NCT07616310Recruiting
Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
A Prospective Randomized Controlled Non-Inferiority Study Comparing the Efficacy of Lesion Excision Versus Rectosigmoid Resection in Pelvic Cytoreductive Surgery for Advanced Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 9 Apr 2026
- Start date
- 10 Jan 2024
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Ovarian cancer
- NCT number
- NCT07616310
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 10 Jan 2024 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received radiotherapy to the abdomen or pelvis before.
Other illness
- Has a history of other malignant tumors or is undergoing other anti-tumor treatments;
- Has severe underlying medical conditions that make surgery intolerable;
- Epithelial ovarian cancer diagnosed incidentally during emergency surgery;
- Secondary cytoreductive surgery for epithelial ovarian cancer;
Other
- Participates in other clinical studies simultaneously;
Who the study is looking for
- Voluntarily participate in this study and sign the informed consent form;
- Age 18-70 years old;
- Primary debulking surgery for epithelial ovarian cancer (including neoadjuvant chemotherapy), with or without abdominal and distant metastasis (≥ IIB stage);
- Colonoscopy negative (no mucosal layer invasion);
- Preoperative imaging (enhanced pelvic MRI) assesses the tumor's involvement of the intestinal surface and/or major parts of the mesentery;
- Eastern Cooperative Oncology Group (ECOG) score \< 3;
- American Society of Anesthesiologists (ASA) score \< 3.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.